Evidence show that the degradation of the AML1‐ETO fusion protein is a target of t(8; 21)q(22;22) AML, and AML‐ETO is a client protein of HSP90 reducing the stability of AML1‐ETO and causing its degradation.13 This evidence concerns the gene RUNX1 and acute myeloid leukemia.